|
|
 |
|
Viewing report
|
|
|
|
The Cancer Outlook to 2007
Business Insights, June 2002
Although many of the gold standard cancer therapies currently used have been marketed for over a decade, the market remains far from mature. The poor efficacy of therapies available and high incidence of disease means that many major pharmaceutical companies see the cancer market as being a key future revenue growth driver. The biopharmaceutical industry has recognised this potential and, in response to this opportunity, has invested heavily in R&D resulting in over 1,000 innovative compounds currently in clinical development. Many of these are now reaching, or about to reach the market, fuelling further expansion in the sector. The NEW management report,. The Cancer Outlook to 2007 is a single source of all the key epidemiological, market, licensing and R&D data which will provide you with a detailed analysis of the current and future dynamics within the cancer market. Its future focus provides an important decision making support for executives across biotechnology and pharmaceutical companies.
Customers who bought this item also bought
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
The Cancer Market Outlook to 2012
Drugs of Tomorrow 2001: Cancer Overview
Cancer Therapeutics Markets
Drug Delivery in Cancer - Technologies, Markets and Companies
The Cancer Market Outlook to 2010
Worldwide Cancer Market: Trend Analysis
Global Cancer Focus Company Directory
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
|
|
|
|
